Assessing Viking Therapeutics (VKTX) Valuation After Strong Multi‑Year Share Price Gains
- If you are wondering whether Viking Therapeutics is still reasonably priced after its recent run, this breakdown will help you frame what the current share price might be implying.
- The stock closed at US$35.20, with returns of 2.7% over 7 days, 4.9% over 30 days, a small year to date decline of 0.6%, and gains of 47.0% over 1 year and 66.0% over 3 years.
- These moves sit against a backdrop of ongoing interest in the company as a clinical stage biotech name, with investors reacting to trial progress updates and broader sector sentiment. Recent attention has focused on how its development pipeline and funding position line up with current expectations for future success.
- Viking currently has a valuation score of 3 out of 6. The rest of…
Source link
